Back to Top

"One of today's leaders in investor relations and shareholder services"

Tag Archives: MJNA

Renowned Doctor Does Study with RSHO-X on LGS (epilepsy) Patients with Incredible Results

MJNA

Lennox-Gastault Syndrome is a severe epileptic disorder that manifests in various forms of seizures. This condition is one of the most severe epilepsies to occur in children. Unfortunately, most LGS patients do not respond well to existing pharmaceutical treatments used to medicate seizures. In many cases, it is impossible to identify the cause of LGS-related seizures, and the seizures themselves are often extremely difficult to manage. LGS may be accompanied by various behavioral and cognitive development issues, and while the condition manifests in childhood, it often continues into adulthood.

Treatment for Lennox-Gastault Syndrome

One of the most difficult aspects of treating LGS in children is the high frequency of seizures that characterizes the syndrome. LGS is also known for being resistant to antiepileptic drugs (AEDs), which can frequently result in debilitating side effects on their own. In a study that ran from January 2016 to February 2017, Dr. Saul …

Continue Reading

Posted in Articles| Tagged , |

HempMeds Continues Domestic and International Growth in 2017

MJNA

HempMeds is a subsidiary of Medical Marijuana, Inc. (MJNA), a publicly traded company that sells a variety of cannabis-based products in the United States and abroad. MJNA has made international headlines with its recent status as an exclusive importer of cannabidiol oil products to Brazil. In February of 2017, the Brazilian government approved a prescription for HempMeds’ Real Scientific Hemp Oil as a treatment for multiple sclerosis. Multiple sclerosis is a debilitating disease that affects the central nervous system, causing pain and a variety of other neuromuscular issues. With Real Scientific Hemp Oil, patients can experience the life-changing benefits of cannabidiol oil without the harmful side effects that accompany most pain medications.

The 2017 decision made by the Brazilian government’s National Health Surveillance Agency (ANVISA) is the first import approved for RSHO as a treatment for multiple sclerosis. More than 2.5 million people suffer from multiple sclerosis worldwide, which …

Continue Reading

Posted in Articles| Tagged , , , , |

Dr. Stuart Titus, Chief Executive Officer of Medical Marijuana, Inc., Discusses Recent News and Events in a New Audio Interview at SmallCapVoice.com

AUSTIN, Texas, Feb. 27, 2017 (GLOBE NEWSWIRE) — Medical Marijuana, Inc. (OTC Pink: MJNA) and SmallCapVoice.com, Inc. (SCV) announced today that a new audio interview with Medical Marijuana, Inc., the first-ever publicly traded cannabis company in the United States, is now available. The interview can be heard at http://smallcapvoice.com/blog/2-10-17-smallcapvoice-interview-with-medical-marijuana-inc-mjna/.

Stuart W. Titus, PhD, the CEO of Medical Marijuana, Inc., called in to SmallCapVoice.com to provide the listening audience with his personal insights into the Company’s recent news and the feedback from his recent trip to speak to investors at The Money Show Orlando about cannabis industry trends and investment opportunities and how biotech companies are producing cannabinoid-based pharmaceuticals that have the potential to improve the daily life of millions across the globe.

About SmallCapVoice.com

SmallCapVoice.com is a recognized corporate investor relations firm, with clients nationwide, known for its ability to help emerging growth companies build a following among retail and …

Continue Reading

Posted in Client News| Tagged , , , |

2-10-17 SmallCapVoice Interview with Medical Marijuana, Inc. (MJNA)

Medical Marijuana, Inc (MJNA)

Stuart W. Titus, PhD, the CEO of Medical Marijuana, Inc. called in to SmallCapVoice.com to provide the listening audience with his personal insights into the Company’s recent news and the feedback from his recent trip to speak to investors at The Money Show Orlando about cannabis industry trends and investment opportunities and how biotech companies are producing cannabinoid-based pharmaceuticals that have the potential to improve the daily life of millions across the globe.

This interview may include forward looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this release. Although the Company believes that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking …

Continue Reading

Posted in Interviews| Tagged , , , |

AXIM IBS Treatment Options and Market Growth in 2017 and Beyond

AXIM

Irritable bowel syndrome is a chronic condition characterized by discomfort and pain in the abdominal region. Sufferers also experience symptoms such as diarrhea, constipation and gas, and it is believed that the condition is adversely affected by anxiety. Anywhere between 25 and 45 million people are affected by IBS in the United States alone, and 2 out of 3 IBS patients are women. The unfortunate reality for IBS sufferers is that there are few effective long-term treatments that manage symptoms without the risk of side effects. As a result, the IBS market presents plenty of opportunities for alternative treatment methods to make a positive impact on patients worldwide.

Medical Marijuana Products

Pharmaceutical industry experts predict that the market for cannabis products could reach 10 percent of the specialty market by the year 2020, with a market value of $20 billion. With a variety of cannabinoids to test and incorporate …

Continue Reading

Posted in Articles| Tagged , , , , |

MJNA Starts Where it Left off in 2016 with Big International Growth

HempMeds

To say that Medical Marijuana, Inc. made headlines in 2016 would be an understatement. In reality, the company known for its CBD hemp oil products took the medical marijuana market by storm with product availability in all 50 states. Since its launch in 2012, MJNA‘s subsidiary company, HempMeds, has made it easier for patients around the country to access relief for a variety of medical issues without the debilitating side effects that often accompany traditional treatment methods. In 2015, the market for hemp products in the United States climbed to $573 million, and that figure is expected to increase dramatically over the next several years. According to estimates from the Hemp Business Journal, the market for CBD is expected to reach $2.1 billion by 2020.

MJNA’s Subsidiary Companies

MJNA‘s subsidiaries include HempMeds, Kannaway, HempMeds MX and HempMeds Brasil. Each of these subsidiaries serves a unique segment of the cannabis …

Continue Reading

Posted in Articles| Tagged , , , , |